Program Overview
The George Shultz Innovation Fund, managed through the University of Chicago’s Polsky Center, awarded $500,000 across two startups in its 2026 competition.
The fund was established to help promising University of Chicago technologies navigate the commercialization gap between academic research and external investment.
Program Impact Since Launch:
• $10.4 million invested
• 83 startups funded
• $327+ million raised in follow-on capital
• 5 successful exits
• 53% of portfolio companies remain active
According to Shyama Majumdar, Senior Director of Science Accelerators and Investments at the Polsky Center:
“I have no doubt that both Signl and Parasol are going to make a big impact on society.”
Strategic Relevance for GAP Leaders
The George Shultz Innovation Fund demonstrates several characteristics of mature university investment programs:
• Long-term institutional commitment to translational funding
• Structured entrepreneur mentorship and pitch preparation
• Integration of investors, industry experts, and commercialization advisors
• Clear focus on follow-on financing readiness
Importantly, the fund’s portfolio performance illustrates the “snowball effect” often observed in successful GAP programs: early investments create successful ventures, which attract follow-on capital, generate exits, and strengthen future fundraising and ecosystem engagement.
For commercialization leaders, the results demonstrate how relatively modest institutional investments can generate substantial downstream economic impact when paired with rigorous venture development support.
Potential Market Applications (Project-Level Detail)
Parasol Medtech ($250,000)
Founder & Chief Medical Officer: Dr. Atman Shah
CEO: Evan Singer
Affiliation: University of Chicago Medicine
Parasol Medtech is developing a novel minimally invasive device for stroke prevention in patients with atrial fibrillation.
The technology addresses limitations associated with current left atrial appendage closure procedures and seeks to provide a safer and more effective intervention.
The George Shultz funding will support:
• Prototype advancement
• Preclinical testing
• Regulatory data generation
• Commercialization and fundraising activities
Market Applications
• Stroke prevention for atrial fibrillation patients
• Structural heart medical devices
• Minimally invasive cardiovascular interventions
Signl ($250,000)
Co-Founder: Dr. Aaron Esser-Kahn
Co-Founder & CSO: Dr. Jeremiah Kim
Signl is developing a new class of immune-modulating medicines that function like a “sound mixer” for the immune system.
The platform enables researchers to reduce vaccine side effects while enhancing immune protection, a capability with broad implications across vaccines and immunotherapies.
The technology has demonstrated success in preclinical animal studies and is initially targeting mRNA vaccines and therapeutics.
The George Shultz funding will support:
• Clinical-grade manufacturing scale-up
• Strategic partnership development
• Team expansion
• Translational development activities
Market Applications
• mRNA vaccine optimization
• Immune system modulation therapies
• Advanced vaccine and biologics development
Read the Full Story
Related Topics
university venture funds, proof-of-concept funding, medtech commercialization, immunotherapy innovation, venture development, university startup investment programs
